Biopharma Vets Launch MOMENTUS, Aiming to Blend AI with Industry Expertise

Lantana, FL – November 6, 2025 – In a sector defined by escalating complexity and rapid innovation, two industry veterans have launched MOMENTUS Biopharma Consulting, a firm positioned to guide pharmaceutical and biotech companies through the challenges of drug development, regulatory approval, and commercialization. The new consultancy, founded by Scott Roberts and John ‘Zeke’ Czekanski, aims to distinguish itself by seamlessly integrating cutting-edge artificial intelligence with decades of hands-on experience.

Roberts and Czekanski, both previously co-founders of successful value-based healthcare consultancy Citrus Health Group, believe the biopharmaceutical landscape demands a more data-driven, agile approach. “The traditional consulting model, while valuable, often struggles to keep pace with the speed of change in our industry,” explains a source close to the founding team. “MOMENTUS is designed to be a more responsive, analytical partner.”

Navigating a Complex Landscape
The timing of MOMENTUS's launch coincides with a period of significant transformation in the biopharmaceutical industry. Regulatory hurdles are increasing globally, demanding meticulous planning and execution. Simultaneously, the pressure to deliver innovative therapies faster and at a lower cost is intensifying. Furthermore, the rise of personalized medicine and the explosion of genomic data are creating unprecedented analytical challenges.

“The regulatory environment is becoming increasingly complex, and companies need expert guidance to navigate the approval process,” says a source familiar with the firm's strategy. “MOMENTUS is building a team with deep expertise in regulatory affairs, pharmacovigilance, and market access.”

AI as a Differentiator

While many consulting firms are exploring the potential of AI, MOMENTUS is positioning it as a core competency. The firm intends to leverage machine learning and data analytics to optimize drug development timelines, identify promising drug candidates, and personalize treatment strategies.

“They're not just talking about AI as a buzzword; they're building it into their core service offerings,” commented one industry analyst. “They plan to utilize AI for predictive modeling, real-world evidence analysis, and identifying unmet medical needs.”

According to internal sources, MOMENTUS is actively investing in proprietary AI platforms and tools, as well as forging partnerships with leading technology companies. The firm anticipates that these investments will enable it to deliver more accurate insights, reduce costs, and accelerate time-to-market for its clients.

Building on a Proven Track Record

The launch of MOMENTUS isn’t the first entrepreneurial venture for Roberts and Czekanski. Their previous firm, Citrus Health Group, quickly established itself as a trusted advisor to major pharmaceutical companies. The firm successfully guided clients through FDA approval processes, developed innovative pricing models for specialty drugs, and ultimately was acquired by a private equity firm in 2018.

“Their previous success demonstrates their ability to build a thriving consultancy and deliver value to clients,” says an industry source. “They understand the nuances of the biopharmaceutical industry and have a proven track record of success.”

The founding team’s experience extends beyond consulting. Roberts previously held leadership positions at Biogen and Merck, while Czekanski held senior roles at Cardinal Health and Pfizer. This combination of consulting and industry experience provides MOMENTUS with a unique perspective and deep understanding of client needs.

Competitive Landscape

MOMENTUS enters a crowded market, competing with established giants like IQVIA, PwC, Deloitte, and McKinsey, as well as specialized firms like ZS Associates. However, the firm believes it can differentiate itself by combining deep industry expertise with a laser focus on AI-driven solutions.

“The big consulting firms offer a broad range of services, but they often lack the specialized expertise and agility of a boutique firm,” suggests one analyst. “MOMENTUS is positioning itself as a nimble, data-driven partner that can deliver tangible results.”

The firm’s initial focus is expected to be on small-to-mid-sized pharmaceutical and biotech companies, which may lack the internal resources to implement sophisticated data analytics solutions. However, MOMENTUS also plans to target larger companies seeking specialized expertise in areas like regulatory affairs and market access.

Looking Ahead

The launch of MOMENTUS reflects a growing trend towards data-driven decision-making in the biopharmaceutical industry. As companies grapple with increasingly complex challenges, they are turning to AI and advanced analytics to gain a competitive edge.

“The future of biopharma consulting is undoubtedly data-driven,” says one industry observer. “Firms that can effectively leverage AI and analytics will be well-positioned to thrive in the years ahead.”

MOMENTUS, with its blend of industry expertise and technological innovation, appears poised to capitalize on this trend. The firm's success will depend on its ability to deliver tangible results for clients and establish itself as a trusted advisor in a rapidly evolving landscape. The firm is betting that its agile structure and focus on next-generation tools will fill a critical gap in the consulting market, positioning it for sustained growth in the years ahead.